Rituximab for the Treatment of Patients with Autoimmune Hepatitis Who are Refractory or Intolerant to Standard Therapy | Zendy

Kelly W. Burak | Zendy; Mark G. Swain | Zendy; Tania Santodomino-Garzon | Zendy; Samuel S. Lee | Zendy; Stefan J. Urbanski | Zendy; Alexander I. Aspinall | Zendy; Carla S. Coffin | Zendy; Robert P. Myers | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rituximab for the Treatment of Patients with Autoimmune Hepatitis Who are Refractory or Intolerant to Standard Therapy

Author(s) -

Kelly W. Burak,

Mark G. Swain,

Tania Santodomino-Garzon,

Samuel S. Lee,

Stefan J. Urbanski,

Alexander I. Aspinall,

Carla S. Coffin,

Robert P. Myers

Publication year - 2013

Publication title -

canadian journal of gastroenterology

Language(s) - English

Resource type - Journals

eISSN - 1916-7237

pISSN - 0835-7900

DOI - 10.1155/2013/512624

Subject(s) - rituximab , medicine , azathioprine , prednisone , autoimmune hepatitis , gastroenterology , refractory (planetary science) , immunology , hepatitis , lymphoma , disease , astrobiology , physics

Although most patients with autoimmune hepatitis (AIH) respond to treatment with prednisone and⁄or azathioprine, some patients are intolerant or refractory to standard therapy. Rituximab is an anti-CD20 monoclonal antibody that depletes B cells and has demonstrated efficacy in other autoimmune conditions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research